Routine board addition with no strategic or operational signal. The option grant represents modest dilution (~57K shares vs ~80M+ outstanding). No immediate trading catalyst, monitor for any future committee assignments or strategic moves.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 23 $20.26entry
- T+1 · 5mo ago +0.35%α +0.39% · $20.33
- T+5 · 5mo ago +4.94%α +3.92% · $21.26
- T+20 · 4mo ago +15.75%α +14.59% · $23.45
- T+60 · 2mo ago −14.59%α −17.38% · $17.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dyne Therapeutics elected Barry E. Greene as an independent Class I director to its board. This is a routine board appointment with standard compensation under the non-employee director program, no material financial or strategic impact.
Key Facts
- Barry E. Greene elected as Class I director effective June 22, 2026
- Not appointed to any board committees
- Received option to purchase 57,463 shares at $20.87 per share, vesting over 3 years
- Annual cash compensation of $45,000 as board member
- No family relationships or transactions with existing directors/officers
Financial Impact
Standard non-employee director compensation, option grant valued at ~$1.2M at grant price, annual cash retainer $45,000
Risk Factors
- No material risk, standard director appointment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001818794-26-000005 |
| Document: 0001818794-26-000005-index-headers.html | 0001818794-26-000005 |
| Document: 0001818794-26-000005-index.html | 0001818794-26-000005 |
| Document: 0001818794-26-000005.txt | 0001818794-26-000005 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers